| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ESM1 |
| Uniprot No | Q9NQ30 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-184aa |
| 氨基酸序列 | WSNNYAVDCPQHCDSSECKSSPRCKRTVLDDCGCCRVCAAGRGETCYRTV SGMDGMKCGPGLRCQPSNGEDPFGEEFGICKDCPYGTFGMDCRETCNCQS GICDRGTGCLKFPFFQYSVTKSSNRFVSLTEHDMASGDGNIVREEVVKEN AAGSPVMRKWLNPRTRHHHHHH |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与ESM1重组蛋白相关的文献摘要概览：
---
1. **文献名称**: *Endocan: A novel prognostic marker for human hepatocellular carcinoma*
**作者**: Liu N. et al.
**摘要**: 本研究利用重组ESM1(Endocan)蛋白分析其在肝癌细胞中的表达及功能，发现ESM1通过调控VEGF信号通路促进肿瘤血管生成，并可作为肝癌预后的潜在生物标志物。
2. **文献名称**: *Recombinant human endocan binds to endothelial cells and modulates their inflammatory response*
**作者**: Béchard D. et al.
**摘要**: 通过大肠杆菌表达系统制备重组人ESM1蛋白，证实其能与内皮细胞表面受体结合，抑制LPS诱导的炎症因子释放，提示其在脓毒症等炎症疾病中的治疗潜力。
3. **文献名称**: *Expression and purification of bioactive recombinant human endocan in Pichia pastoris*
**作者**: Chen Y. et al.
**摘要**: 采用毕赤酵母系统高效表达具有糖基化修饰的重组ESM1蛋白，验证其促进内皮细胞迁移和血管形成的活性，为后续药物开发提供高纯度蛋白来源。
---
以上文献涵盖ESM1重组蛋白的制备方法(如大肠杆菌/酵母表达)、功能研究(血管生成、炎症调控)及临床关联(癌症预后)，均为该领域的关键研究。
**Background of ESM1 Recombinant Protein**
Endothelial cell-Specific Molecule 1 (ESM1), also known as endocan, is a soluble proteoglycan predominantly expressed by vascular endothelial cells. First identified in 1996. ESM1 plays a critical role in regulating cell adhesion, inflammation, and angiogenesis. It interacts with key signaling pathways, including vascular endothelial growth factor (VEGF) and Notch, influencing endothelial cell proliferation, migration, and vascular permeability. Structurally, ESM1 contains a mature polypeptide chain of 165 amino acids, featuring a cysteine-rich N-terminal domain and a chondroitin sulfate glycosaminoglycan chain attachment site, which contributes to its biological activity.
The recombinant form of ESM1 (rESM1) is produced using biotechnological platforms, such as bacterial or mammalian expression systems, to ensure proper post-translational modifications. Recombinant ESM1 retains functional properties comparable to the native protein, enabling its use in mechanistic studies and therapeutic development. Its role in pathological conditions, particularly cancer and inflammatory diseases, has garnered significant interest. Elevated ESM1 levels correlate with tumor progression, metastasis, and poor prognosis in cancers like glioblastoma, lung, and renal carcinoma, likely due to its pro-angiogenic and immune-modulatory effects in the tumor microenvironment.
Research on rESM1 has expanded into diagnostic and therapeutic applications. It is explored as a biomarker for endothelial dysfunction and a target for anti-angiogenic therapies. Preclinical studies suggest that inhibiting ESM1 disrupts tumor vasculature and enhances chemotherapy efficacy. Additionally, recombinant ESM1 serves as a tool to study endothelial cell biology and screen potential drugs targeting angiogenesis-related pathways. Despite progress, challenges remain in optimizing its stability, delivery, and specificity for clinical translation. Overall, ESM1 recombinant protein represents a promising avenue for understanding vascular pathologies and developing precision therapies.
×
